Immunovant IncNASDAQ IMVT Stock Report

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 124 full-time employees. The company went IPO on 2019-05-14. The firm is focused on developing treatments for patients with autoimmune diseases. The firm's product candidate, batoclimab, is a fully human, monoclonal antibody targeting the neonatal fragment crystallizable receptor. Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. The company is developing batoclimab for Myasthenia Gravis (MG), Thyroid Eye Disease (TED) and Warm Autoimmune Hemolytic Anemia (WAIHA). The firm is conducting a phase I drug-drug interaction (DDI) study in healthy volunteers to characterize the pharmacokinetic (PK) profile of atorvastatin with and without the coadministration of batoclimab.